Handley D J, Matta K L, Piver M S, Diakun K R
Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263.
Immunol Invest. 1991 Feb;20(1):21-32. doi: 10.3109/08820139109054922.
The CA 125 antigenic determinant has been shown to be elevated in the serum of ovarian cancer patients and is a useful prognostic marker. The chemical epitope which characterizes the CA 125 antigen is found on a high molecular weight glycoprotein and has been suggested to be carbohydrate in nature. This study was undertaken to establish the relationship of a carbohydrate to the epitope recognized by the monoclonal antibody, OC 125. Along this line a carbohydrate structure conjugated to bovine serum albumin (BSA), was enzymatically sialylated using a purified sialyltransferase to yield NeuAcGal[GlcNAc]GalNAc-OC6H4N = N-BSA. This sialylated product was used to immunize a goat and two rabbits for the development of polyclonal antisera. The resultant antisera were tested against related carbohydrates in EIA biased competitive inhibition assays. It was determined that the GlcNAc(beta 1-6)GalNAc residue was immunologically dominant for all antisera tested. As the immune response matured (greater than 40 days), there was an increase in the proportion of the antibodies that were directed to the NeuAc(alpha 2-3)Gal(beta 1-3)GalNAc residue compared to the nonsialylated form. Known CA 125 molecules did not inhibit the binding of raised antisera to the sialylated product, nor did the sialylated product react with OC 125 monoclonal antibodies. It was therefore concluded that the carbohydrate structure in question is not the epitope, or is not a large enough part of the epitope to be recognized in these assays by the OC 125 monoclonal antibodies.
CA 125抗原决定簇在卵巢癌患者血清中已被证明会升高,是一种有用的预后标志物。表征CA 125抗原的化学表位存在于一种高分子量糖蛋白上,有人认为其本质是碳水化合物。本研究旨在确定一种碳水化合物与单克隆抗体OC 125所识别的表位之间的关系。为此,将一种与牛血清白蛋白(BSA)偶联的碳水化合物结构,用纯化的唾液酸转移酶进行酶促唾液酸化,得到NeuAcGal[GlcNAc]GalNAc-OC6H4N = N-BSA。这种唾液酸化产物用于免疫一只山羊和两只兔子,以制备多克隆抗血清。所得抗血清在酶免疫分析偏倚竞争抑制试验中针对相关碳水化合物进行检测。结果确定,对于所有检测的抗血清,GlcNAc(β1-6)GalNAc残基在免疫上占主导地位。随着免疫反应的成熟(超过40天),与非唾液酸化形式相比,针对NeuAc(α2-3)Gal(β1-3)GalNAc残基的抗体比例有所增加。已知的CA 125分子不会抑制所产生的抗血清与唾液酸化产物的结合,唾液酸化产物也不与OC 125单克隆抗体发生反应。因此得出结论,所讨论的碳水化合物结构不是表位,或者不是表位中足够大的部分,以至于在这些试验中不能被OC 125单克隆抗体识别。